USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $30.39 and traded as high as $33.95. USANA Health Sciences shares last traded at $33.46, with a volume of 103,990 shares trading hands.
Wall Street Analyst Weigh In
Separately, Wall Street Zen upgraded shares of USANA Health Sciences from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd.
Check Out Our Latest Stock Report on USNA
USANA Health Sciences Price Performance
The company has a market capitalization of $605.35 million, a P/E ratio of 17.86, a P/E/G ratio of 1.05 and a beta of 0.64. The stock's 50 day simple moving average is $30.41 and its two-hundred day simple moving average is $30.28.
USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its earnings results on Tuesday, April 22nd. The company reported $0.73 earnings per share for the quarter, topping analysts' consensus estimates of $0.70 by $0.03. USANA Health Sciences had a net margin of 3.98% and a return on equity of 8.94%. The company had revenue of $249.54 million during the quarter, compared to the consensus estimate of $243.08 million. During the same period in the previous year, the firm posted $0.86 earnings per share. As a group, equities research analysts expect that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.
Insider Activity at USANA Health Sciences
In other USANA Health Sciences news, CFO G Doug Iiekking sold 4,548 shares of the stock in a transaction on Friday, May 9th. The shares were sold at an average price of $29.61, for a total value of $134,666.28. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Walter Noot sold 6,291 shares of USANA Health Sciences stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $30.29, for a total transaction of $190,554.39. The disclosure for this sale can be found here. Insiders sold 12,013 shares of company stock worth $360,149 over the last 90 days. 0.63% of the stock is currently owned by company insiders.
Institutional Trading of USANA Health Sciences
Several hedge funds have recently added to or reduced their stakes in the business. Amundi raised its position in shares of USANA Health Sciences by 85.3% during the fourth quarter. Amundi now owns 4,872 shares of the company's stock worth $170,000 after purchasing an additional 2,243 shares during the period. Royce & Associates LP increased its position in shares of USANA Health Sciences by 17.4% during the fourth quarter. Royce & Associates LP now owns 38,914 shares of the company's stock worth $1,397,000 after acquiring an additional 5,771 shares in the last quarter. Quantbot Technologies LP bought a new stake in USANA Health Sciences in the 4th quarter valued at $132,000. American Century Companies Inc. boosted its stake in USANA Health Sciences by 12.3% in the 4th quarter. American Century Companies Inc. now owns 233,797 shares of the company's stock worth $8,391,000 after purchasing an additional 25,522 shares during the period. Finally, KLP Kapitalforvaltning AS bought a new position in USANA Health Sciences during the 4th quarter worth about $83,000. Institutional investors and hedge funds own 54.25% of the company's stock.
USANA Health Sciences Company Profile
(
Get Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Recommended Stories
Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
